BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 28250960)

  • 1. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
    Frey MK; Pothuri B
    Gynecol Oncol Res Pract; 2017; 4():4. PubMed ID: 28250960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Homologous Recombination Deficiency in Ovarian Cancer.
    Ratnaparkhi R; Javellana M; Jewell A; Spoozak L
    Curr Treat Options Oncol; 2024 Feb; 25(2):237-260. PubMed ID: 38300479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Determinants of Homologous Recombination Deficiency across Human Cancers.
    Qing T; Wang X; Jun T; Ding L; Pusztai L; Huang KL
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    Rabban JT; Chen LM; Devine WP
    Surg Pathol Clin; 2022 Jun; 15(2):219-234. PubMed ID: 35715159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.
    Torres-Esquius S; Llop-Guevara A; Gutiérrez-Enríquez S; Romey M; Teulé À; Llort G; Herrero A; Sánchez-Henarejos P; Vallmajó A; González-Santiago S; Chirivella I; Cano JM; Graña B; Simonetti S; Díaz de Corcuera I; Ramon Y Cajal T; Sanz J; Serrano S; Otero A; Churruca C; Sánchez-Heras AB; Servitja S; Guillén-Ponce C; Brunet J; Denkert C; Serra V; Balmaña J
    JAMA Netw Open; 2024 Apr; 7(4):e247811. PubMed ID: 38648056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
    Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Haunschild CE; Tewari KS
    Gynecol Oncol; 2021 Jan; 160(1):333-345. PubMed ID: 33055011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort.
    Rădoi VE; Țurcan M; Maioru OV; Dan A; Bohîlțea LC; Dumitrescu EA; Gheorghe AS; Stănculeanu DL; Thodi G; Loukas YL; Săbău ID
    Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial Cancers in
    Smith ES; Da Cruz Paula A; Cadoo KA; Abu-Rustum NR; Pei X; Brown DN; Ferrando L; Sebastiao APM; Riaz N; Robson ME; Soslow RA; Reis-Filho JS; Mandelker D; Weigelt B
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
    Levine MD; O'Malley DM; Haight PJ; Senter L; Wagner V; Bixel KL; Cohn DE; Copeland LJ; Cosgrove CM; McLaughlin EM; Backes FJ
    Gynecol Oncol Rep; 2023 Apr; 46():101173. PubMed ID: 37082521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
    Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
    Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.